HANG YICK HLDGS (01894) has granted a total of 3.077 million share options.

06:31 25/08/2026

Hengyi Holdings (01894) announced that on August 24, 2026 (the grant date), the company has granted a total of 3.077 million share options (the options) to two participants (the grantees) under its share option scheme adopted on September 19, 2018, for the subscription of a total of 3.077 million ordinary shares with a par value of HK$0.2 each in the company's share capital, representing approximately 1.34% of the total number of shares in issue as of the announcement date, subject to the acceptance by the grantees.

HANG YICK HLDGS (01894) announced that on August 24, 2026 (the grant date), the company granted a total of 3.077 million options (the options) to two participants (the grantees) in accordance with its share option scheme adopted on September 19, 2018, for the subscription of a total of 3.077 million ordinary shares of the company, each with a nominal value of HK$0.2, representing approximately 1.34% of the total issued share capital as of the date of this announcement, subject to acceptance by the grantees.

TUYA-W (02391) released its interim results, with a net profit of 34.40 million USD, an increase of 45.8% year-on-year.

PERENNIAL INT'L (00725) has sold a total of 40,000 shares of Alibaba.

ANTENGENE-B(06996): ATG-201 for the treatment of B cell-mediated autoimmune diseases has received HREC approval for the Phase I ATTRACT study in Australia.

TUYA-W (02391) released its interim results, with a net profit of 34.40 million USD, an increase of 45.8% year-on-year.

PERENNIAL INT'L (00725) has sold a total of 40,000 shares of Alibaba.

ANTENGENE-B(06996): ATG-201 for the treatment of B cell-mediated autoimmune diseases has received HREC approval for the Phase I ATTRACT study in Australia.